Research programme: poliovirus vaccines - Batavia Biosciences
Latest Information Update: 28 Feb 2022
At a glance
- Originator Batavia Biosciences
- Developer Batavia Biosciences; PATH
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Poliomyelitis
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Poliomyelitis(Prevention) in Netherlands (PO)
- 07 Feb 2019 Univercells and consortium partners Batavia Biosciences and Merck receives grant extension from Bill & Melinda Gates Foundation for the development of poliovirus vaccines
- 23 Jan 2018 Univercells and consortium partners Batavia Biosciences and Natrix Separations receive grant from Bill & Melinda Gates Foundation for the development of poliovirus vaccines